Eli Lilly Launches Multi-Dose KwikPen for Zepbound, Boosting Convenience and Market Lead
Eli Lilly & Co. has introduced a new multi-dose injection pen for its obesity drug, Zepbound. This new device, called KwikPen, provides a month's supply of doses in a single pen.
Cash-paying patients can obtain the KwikPen through Lilly's direct-to-consumer platform, LillyDirect, with prices for the lowest dose level starting at $299 per month. This new option is designed to offer increased convenience for patients.
This new option is designed to offer increased convenience for patients by reducing the number of devices required monthly, as one pen delivers four weekly doses of Zepbound.
Previously, patients used a single-dose autoinjector weekly or single-dose vials that required drawing medication into a syringe. The KwikPen significantly streamlines this process.
This development aims to sustain the demand for Zepbound, which has experienced significant growth since its introduction in late 2023. LillyDirect has played a key role in Zepbound's market expansion.
Zepbound's success has enabled Eli Lilly to secure a majority share of the weight-loss drug market, surpassing Novo Nordisk. The drug's financial impact on the company has been substantial.
In the company's fourth quarter, Zepbound generated $4.2 billion in U.S. revenue, marking a 122% increase from the prior year. The Food and Drug Administration (FDA) approved a label expansion for Zepbound to incorporate the multi-dose device.
The KwikPen technology is already utilized for other Lilly medications, such as the diabetes drug Mounjaro. Ilya Yuffa, president of Lilly USA and Global Customer Capabilities, indicated that the KwikPen's introduction supports individuals managing obesity.